Retracted:Preparation and characterization of crosslinked and non-crosslinked polycaprolactone fumarate (PCLF) NPs as carriers for doxorubicin HCl

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 7, 2011, Pages 797-805

  Shokri, Narges ^a   Javar, Hamid Akbari ^a,b   Fouladdel, Shamileh ^a   Khalaj, Ali ^a   Dinarvand, Rasoul ^a   Azizi, Ebrahim ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Crosslinked PCLF NPs; Doxorubicin HCl; Nanoparticles

Indexed keywords

1 VINYL 2 PYRROLIDINONE; BENZOYL PEROXIDE; DOXORUBICIN; FUMARIC ACID; NANOPARTICLE; POLYCAPROLACTONE FUMARATE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CROSS LINKING; DRUG DELIVERY SYSTEM; DRUG TARGETING; HEAT TREATMENT; HYDROPHOBICITY; IN VITRO STUDY; NANOANALYSIS; NANOFABRICATION; NANOPHARMACEUTICS; PARTICLE SIZE; PH MEASUREMENT; PRECIPITATION; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

EID: 80051650630     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: TB

References (26)

1. Abou Zeid DM, Muller RJ, Deckwer WD (2004). Biodegradation of aliphatic homopolyesters and aliphatic-aromatic copolyesters by anaerobic microorganisms. Biomacromolecules, 5: 1687-1697.
2. Bilati U, Allemann E, Doelker E (2005). Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur. J. Pharm. Sci., 24: 67-75.
3. Dirk W., Grijpma QH, Jan F (2005). Preparation of biodegradable networks by photo-crosslinking lactide, ε-caprolactone and trimethylene carbonate-based oligomers functionalized with fumaric acid monoethyl ester. Biomaterials, 26: 2795-2802.
4. Eldsater C, Erlandsson B, Renstad R, Albertsson AC, Karlsson S (2000). The biodegradation of amorphous and crystalline regions in film-blown poly(caprolactone). Polymer, 41: 1297-1304.
5. El Malah Y, Nazzal S (2006). Hydrophilic matrices: Application of Placket-Burman screening design to model the effect of POLYOX-Shokri et al. 805 carbopol blends on drug release. Int. J. Pharm., 309: 163-170.
6. Hakkarainen M, Albertsson AC (2002). Heterogeneous biodegradation of poly-caprolactone-low molecular weight products and surface changes. Macromol. Chem. Phys., 203: 1357-1363.
7. Harrison KL, Jenkins MJ (2004). The effect of crystallinity and water absorption on the dynamic mechanical relaxation behaviour of polycaprolactone. Polym. Int., 53:1298-1304.
8. Huatan H, Collett JH, Attwood D (1995). The microencapsulation of protein using a novel ternary blend based on poly (caprolactone). J. Microen, 12: 557-567.
9. Jenkins MJ, Harrison KL (2006). The effect of molecular weight on the crystallization kinetics of polycaprolactone. Polym. Adv. Technol., 17: 474-478.
10. Kim SY, Ha JCH, Lee YM (2000). Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide)/poly(caprolactone) (PCL) amphiphilic block copolymeric nanospheres: II. Thermo-responsive drug release behaviors. J. Cont. Rel., 65: 345-358.
11. Kim SY, Lee YM (2001). Taxol-loaded block copolymer nanospheres composed of methoxy poly (ethylene glycol) and poly (caprolactone) as novel anticancer drug carriers. Biomaterials, 22: 1697-1704.
12. Lamprecht A, Ubruch N, Hombreiro Perez M, Lehr C M, Hoffman M, Maincent P (1999). Biodegradable monodispersed nanoparticles prepared by pressure homogenization emulsification. Int. J. Pharm., 184: 97-105.
13. Matsumura Y, Maeda H (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumor tropic accumulation of proteins and antitumor agent SMANCS. Cancer Res., 46: 6387-6392.
14. Muller RH (1991). Colloidal carriers for controlled drug delivery and targeting modification, characterization and in vivo distribution. CRC Press, Boca Raton, FL, pp. 57-97.
15. Paliwal R, Rai Sh, Vaidya B (2009). Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomed., 5:184-191.
16. Park JS, Woo DG, Sun BK (2007). In vitro and in vivo test of PEG/PCLbased hydrogel scaffold for cell delivery application. J. Cont. Rel., 124: 51-59.
17. Peracchia MT, Fattal E, Desmaële D (1999). Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Cont. Rel., 60:121-128.
18. Shin H, Ruhe PQ, Mikos AG, Jansen JA (2003). In vivo bone and soft tissue response to injectable, biodegradable oligo(poly(ethylene glycol) fumarate) hydrogels. Biomaterials, 24: 3201-3211.
19. Shokri N, Akbari Javar H, Azizi E (2011). Preparation and evaluation of poly(caprolactone fumarate) nanoparticles containing doxorubicin HCl. Daru J. Pharm. Sci., 19: 12-22.
20. Sou K, Inenaga Sh, Takeoka Sh, Tsuchida E (2008). Loading of curcumin into macrophages using lipid-based nanoparticles. Int. J. Pharm. Pharmaceut. Nanotechnol., 352: 287-293.
21. Wang Sh, Lu L, Gruetzmacher J, Currier B, Yaszemski M (2006). Synthesis and characterizations of biodegradable and crosslinkable poly(e-caprolactone fumarate), poly(ethylene glycol fumarate), and their amphiphilic copolymer. Biomaterials, 27: 832-841.
22. Wang Sh, Yaszemski M, Knight A, Gruetzmacher J, Windebank A, Lu L (2009). Photo-crosslinked poly(e-caprolactone fumarate) networks for guided peripheral nerve regeneration: Material properties and preliminary biological evaluations. Acta Biomaterialia, 5: 1531-1542.
23. Wang Sh, Yaszemski M, Gruetzmacher JA, Lu L (2008). Photocrosslinked poly(caprolactone fumarate) networks: Roles of crystallinity and crosslinking density in determining mechanical properties. Polym, 49: 5692-5699.
24. Yang R, Shim WS, Cui FD (2009). Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int. J. Pharm., 371: 142-147.
25. Zhang J, Chen XG, Li YY, Liu CS (2007). Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin. Nanomed., 3: 258-265.
26. Zhou SH, Deng X, Yang H (2003). Biodegradable poly(caprolactone)-poly(ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials, 24: 3563-3670.